Novartis has jettisoned an anti-cancer protein from its pipeline after the molecule failed to shrink tumors in 30 patients ...

Politico has reported that the White House isn’t happy with the FDA’s recent actions surrounding vaccines, fueling public scrutiny of internal decision-making at the regulator. | Politico has reported ...

Johnson & Johnson has paused further enrollment in a phase 2b trial of its AC Immune-partnered Alzheimer’s candidate, leaving analysts to speculate that recruitment challenges may be the culprit.

Sanofi has backed the $75 million series B of a rhinovirus-focused biotech with a former FDA acting commissioner at the helm. | Sanofi has backed the $75 million series B of a rhinovirus-focused ...

Newly FDA-cleared blood tests are now making it easier for doctors to diagnose Alzheimer’s disease. But could a single blood test also predict when their symptoms will appear? | Newly FDA-cleared ...

A new entrant in the race to shepherd antibodies for Alzheimer’s disease across the blood-brain barrier has emerged. | A new entrant in the race to shepherd antibodies for Alzheimer’s disease across ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Danaher Corp. is snapping up patient monitoring medtech Masimo in a $9.9 billion deal aimed at strengthening its diagnostics ...

Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.

Unnatural Products is proving to be a natural at securing partnerships, this time linking up with Novartis in a deal that could garner up to $1.7 billion in biobucks.

Sanofi and Teva had already shown in late 2024 that the anti-TL1A antibody, called duvakitug, improved outcomes in ulcerative ...

The FDA has accepted Moderna’s revised influenza vaccine filing days after controversially refusing to review the original submission, putting the biotech on track to win approval in time for the 2026 ...